Apollomics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Apollomics, Inc. (APLM) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oncology therapies that harness the immune system and target specific molecular pathways to treat cancer. The company develops a broad pipeline of nine product candidates across 11 programs, including six in clinical development; key candidates comprise vebreltinib (APL-101), an oral c-Met inhibitor in Phase 2 trials for non-small cell lung cancer (NSCLC), glioblastoma multiforme (GBM) and other MET-driven solid tumors; uproleselan (APL-106), an E-selectin antagonist in trials for relapsed/refractory acute myeloid leukemia (AML); APL-102, a multi-tyrosine kinase inhibitor in Phase 1; APL-122, an ErbB family inhibitor for brain cancers; immuno-oncology agents APL-501, APL-502 and APL-801; and others such as genolimzumab (PD-1 inhibitor) and EO-1001 (EGFR/HER2/HER4 bispecific antibody). Founded in 2015 and headquartered in Foster City, California, Apollomics maintains operations across the United States, China, Australia and Taiwan, with licensing partnerships including Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd. in China and LaunXP Biomedical Co., Ltd. in Taiwan. Recent developments include a strategic collaboration with LaunXP announced in 2025 providing $10 million upfront payment plus up to $50 million in milestones and royalties for vebreltinib combination therapy development; $4.1 million in PIPE funding on September 3, 2025; appointment of a new board and management team; and continuation of the global Phase 2 SPARTA trial for APL-101 with data from over 280 patients, alongside existing Chinese approvals for APL-101 in MET-amplified NSCLC and GBM.
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Apollomics Inc. Announces $2.0 Million Bridge Financing
Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March
Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest
Apollomics Reports First Half 2025 Financial Results
Apollomics Announces Settlement of Cayman Litigation
Apollomics Announces Changes to its Board of Directors and Composition of Committees
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Nasdaq Resumes Trading in Apollomics Inc.
Apollomics, Inc. Company Operational Continuity Update
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial